Evaluation of Lasofoxifene Versus Fulvestrant in Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation
- Status
- COMPLETED
- Phase
- PHASE2
Clinical Trials Related to Fulvestrant
Related studies linked through entity extraction aliases.
Pyrotinib, Dalpiciclib(SHR6390) and Endocrine Therapy in Subjects With Dual-receptor Positive(ER+/HER2+) Advanced Breast Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1/PHASE2
MEN1611 With Trastuzumab (+/- Fulvestrant) in Metastatic Breast Cancer
- Status
- COMPLETED
- Phase
- PHASE1
Radiation Therapy, Palbociclib, and Hormone Therapy in Treating Breast Cancer Patients With Bone Metastasis
- Status
- COMPLETED
- Phase
- PHASE2
HOPE: Olaparib, Palbociclib and Fulvestrant in Patients With BRCA Mutation-associated, HR+, HER2-metastatic Breast Cancer
- Status
- COMPLETED
- Phase
- PHASE1
Evaluating Cancer Response to Treatment With Abemaciclib and Fulvestrant in Women With Recurrent Endometrial Cancer
- Status
- COMPLETED
- Phase
- PHASE2
Palbociclib and Letrozole or Fulvestrant in Treating Patients With Estrogen Receptor Positive, HER2 Negative Metastatic Breast Cancer
- Status
- COMPLETED
- Phase
- PHASE2
A Phase II Study Comparing The Efficacy Of Venetoclax + Fulvestrant Vs. Fulvestrant In Women With Estrogen Receptor-Positive, Her2-Negative Locally Advanced Or Metastatic Breast Cancer Who Experienced Disease Recurrence Or Progression During Or After CDK4/6 Inhibitor Therapy
- Status
- TERMINATED
- Phase
- PHASE2
Anti-hormonal Therapie With Ribociclib in HR-positive / HER2- Negative Metastatic Breast Cancer
- Status
- COMPLETED
- Phase
- PHASE2
T-VEC With Chemotherapy or Endocrine Therapy in Treating Participants With HER2- Negative Breast Cancer
- Status
- COMPLETED
- Phase
- PHASE1
Fulvestrant Plus Abemaciclib in Women With Advanced Low Grade Serous Carcinoma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Study of the Molecular Features of Postmenopausal Women With HR+ HER2-negative aBC on First-line Treatment With Ribociclib and Letrozole and, in Patients With a PIK3CA Mutation, on Second-line Treatment With Alpelisib Plus Fulvestrant
- Status
- COMPLETED
- Phase
- PHASE3
Endocrine Therapy Plus CDK4/6 in First or Second Line for Hormone (SONIA) Receptor Positive Advanced Breast Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
Study of Pembrolizumab Plus Fulvestrant in Hormone Receptor Positive, HER-2 Negative Advanced/Metastatic Breast Cancer Patients
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Fulvestrant and Palbociclib With or Without Copanlisib in Treating Patients With Hormone Receptor Positive, HER2 Negative, Stage IV Breast Cancer
- Status
- WITHDRAWN
- Phase
- PHASE2
Modular Study to Evaluate CT7001 Alone in Cancer Patients With Advanced Malignancies
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
A Study of Debio 1347 Plus Fulvestrant in Patients With Metastatic Breast Cancer
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
HR+/HER2- Advanced Breast Cancer and Endocrine Resistance
- Status
- TERMINATED
- Phase
- PHASE2
AZD5363 in Patients With Advanced Solid Tumors Harboring AKT Mutations
- Status
- COMPLETED
- Phase
- PHASE1